All Stories

  1. Association of Easier Biologic Access with Remission and Other Clinical Outcomes in Severe Asthma: A Global Real-World Study
  2. The Australia New Zealand respiratory audit programme: a new paradigm to improve respiratory care
  3. General practitioners’ attitudes towards liquid biopsy as a diagnostic test for advanced lung cancer
  4. New Zealand Chronic Obstructive Pulmonary Disease Guidelines: 2025 update
  5. Response to Biologics Along a Gradient of T2 Involvement in Patients With Severe Asthma: A Data-Driven Biomarker Clustering Approach
  6. Review of the New Zealand Asthma and Respiratory Foundation’s New Zealand Adolescent and Adult Asthma guidelines
  7. Treatable Trait Guided Asthma Management: A Feasibility Study
  8. Environmental impact of inhaled medicines: A Thoracic Society of Australia and New Zealand position statement
  9. Real‐world biologics response and super‐response in the International Severe Asthma Registry cohort
  10. Evaluating the Feasibility of a Community Pharmacy-Delivered Behaviour Change Intervention to Reduce Reliever Reliance in Asthma
  11. Treatable trait guided asthma management: biomarker changes and responder analysis
  12. Prevention of Re-Hospitalization for Acute Exacerbations: Perspectives of People with Chronic Obstructive Pulmonary Disease: A Qualitative Study
  13. Taking Charge After Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Randomized Controlled Feasibility Trial of a Psychologically Informed Self-Management Intervention
  14. A survey of adult respiratory and sleep services in Aotearoa New Zealand: inequities in the provision of adult respiratory and sleep services
  15. Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial
  16. Asthma control with ICS-formoterol reliever versus maintenance ICS and SABA reliever therapy: a post hoc analysis of two randomised controlled trials
  17. Rhinothermy delivered by nasal high flow therapy in the treatment of the common cold: a randomised controlled trial
  18. Defining a Severe Asthma Super-Responder: Findings from a Delphi Process
  19. Epinephrine (adrenaline) compared to selective beta-2-agonist in adults or children with acute asthma: a systematic review and meta-analysis
  20. Study protocol for a feasibility trial in community pharmacy of a personalised behaviour change intervention to reduce reliever reliance and overuse in individuals with asthma.
  21. Adrenaline (epinephrine) compared to selective beta-2-agonist in adults or children with acute asthma: a systematic review and meta-analysis
  22. Severe asthma assessment, management and the organisation of care in Australia and New Zealand: expert forum roundtable meetings
  23. Engaging Māori with qualitative healthcare research using an animated comic
  24. ICS-formoterol reliever versus ICS and short-acting β2-agonist reliever in asthma: a systematic review and meta-analysis
  25. Systematic review of the comparison between adrenaline (epinephrine) and selective ß2-agonist in the setting of adults or children with acute asthma
  26. Patient preferences for asthma management: a qualitative study
  27. Patient preferences for asthma management: a qualitative study
  28. What matters most to patients when choosing treatment for mild–moderate asthma? Results from a discrete choice experiment
  29. Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial
  30. Self-titration of inhaled corticosteroid and β2-agonist in response to symptoms in mild asthma: a pre-specified analysis from the PRACTICAL randomised controlled trial
  31. Patient preferences for symptom-driven or regular preventer treatment in mild to moderate asthma: findings from the PRACTICAL study, a randomised clinical trial
  32. P226 Combined analysis of two randomized controlled trials of budesonide/formoterol reliever therapy in adults with mild asthma
  33. Pre-apneic capnography waveform abnormalities during procedural sedation and analgesia
  34. Late Breaking Abstract - Open-label trial of budesonide/formoterol reliever therapy in mild asthma
  35. Which traits to target in asthma? Importance of treatable traits varies depending on desired outcome
  36. What do patients want? Preferences for two asthma regimens in mild/moderate asthma
  37. Discrete choice experiments identifying attributes influencing treatment preference in mild asthma
  38. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial
  39. Nasal gene expression changes with inhaled corticosteroid treatment in asthma
  40. Sequence analysis of capnography waveform abnormalities during nurse-administered procedural sedation and analgesia in the cardiac catheterization laboratory
  41. Protocol for a randomised, single-blind, two-arm, parallel-group controlled trial of the efficacy of rhinothermy delivered by nasal high flow therapy in the treatment of the common cold
  42. Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma
  43. Nasal high‐flow therapy compared with non‐invasive ventilation in COPD patients with chronic respiratory failure: A randomized controlled cross‐over trial
  44. Severe Asthma Global Evaluation (SAGE): An Electronic Platform for Severe Asthma
  45. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report
  46. The duration of anti-inflammatory action of fluticasone furoate (FF) assessed via exhaled nitric oxide (FeNO) in asthmatics following administration of FF/vilanterol (VI)
  47. Serum periostin levels in adults of Chinese descent: an observational study
  48. Type 2 Biomarkers and Prediction of Future Exacerbations and Lung Function Decline in Adult Asthma
  49. Oxygen versus air-driven nebulisers for exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial
  50. Late Breaking Abstract - Which treatable traits matter? Prevalence of treatable traits and risk of exacerbation in a random population sample with asthma
  51. Accuracy and precision of transcutaneous carbon dioxide monitoring: a systematic review and meta-analysis
  52. Serum periostin levels following small bone fractures, long bone fractures and joint replacements: an observational study
  53. Change in biomarkers of type-2 inflammation following severe exacerbations of asthma
  54. Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial
  55. Randomised controlled trial of rhinothermy for treatment of the common cold: a feasibility study
  56. The inhaled corticosteroid/long-acting β-agonist maintenance and reliever therapy regimen: where to from here?
  57. Treatable traits of chronic airways disease
  58. Phenotypes of symptomatic airways disease in China and New Zealand
  59. Nasal high flow therapy and PtCO2 in stable COPD: A randomized controlled cross-over trial
  60. Late Breaking Abstract - The duration of anti-inflammatory action of fluticasone furoate (FF) assessed via exhaled nitric oxide (FeNO) in asthmatics following administration of FF/vilanterol (VI)
  61. Oxygen compared to air driven nebulisers for acute exacerbations of COPD: a randomised controlled trial
  62. Description of the protocol for the PRACTICAL study: a randomised controlled trial of the efficacy and safety of ICS/LABA reliever therapy in asthma
  63. Longitudinal variation of serum periostin levels in adults with stable asthma
  64. RCT of the effect of berryfruit polyphenolic cultivar extract in mild steroid-naive asthma: a cross-over, placebo-controlled study
  65. Day-time variation of serum periostin in asthmatic adults treated with ICS/LABA and adults without asthma
  66. Reference ranges for serum periostin in a population without asthma or chronic obstructive pulmonary disease
  67. Serum periostin in obstructive airways disease
  68. Randomised controlled trial of topical kanuka honey for the treatment of acne
  69. Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults
  70. A single-blind randomised controlled trial of topical kanuka honey for the treatment of nappy rash
  71. Randomised controlled trial of topical kanuka honey for the treatment of rosacea
  72. Randomised controlled trial of topical kanuka honey for the treatment of cold sores
  73. S43 Real World Experience Of The Use Of Pet-ct For Distinguishing Between Benign Pleural Disease And Malignant Mesothelioma
  74. A randomised controlled trial of topical Kanuka honey for the treatment of psoriasis
  75. A randomised controlled trial of topical Kanuka honey for the treatment of eczema
  76. Topical kanuka honey for the treatment of nappy rash
  77. Letter in response to Tashkinet al: limited generalisability of uplift findings to clinical practice
  78. Topical kanuka honey for the treatment of rosacea
  79. Limited generalisability of UPLIFT findings to clinical practice: Table 1
  80. Efficacy of Micromobile Foot Compression Device in Increasing Lower Limb Venous Blood Flow
  81. A half doubling dose change in bronchial hyperresponsiveness in a population represents an important difference
  82. Restriction of LABA use to combination ICS/LABA inhaler therapy in asthma
  83. Bronchodilator responsiveness: interpret with caution
  84. Proposed MHRA changes to UK children's paracetamol dosing recommendations: modelling study
  85. Towards individualised medicine for airways disease: identifying clinical phenotype groups: Figure 1–
  86. Individualized treatment for asthma
  87. British National Formulary for Children: the risk of inappropriate paracetamol prescribing
  88. Towards individualised treatment in COPD